Congenital Pulmonary Airway Malformation
Conditions
Interventions
R group:Remimazolam was administered via continuous infusion at a rate of 1.0–2.5 mg/kg/h
S group:In Group S, sevoflurane was administered by inhalation to maintain MAC 0.7-1.0
Sponsors
Bozhou People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children under 2 years old, ASA II, undergoing lung resection surgery due to congenital pulmonary cystadenoma
Exclusion criteria
Exclusion criteria: 1. Exclude those with congenital heart disease, recent respiratory tract infections, allergies to the study drug, or allergies to any sedatives, analgesics, antiemetics, or antipruritics taken within 24 hours before surgery; 2. Those with respiratory depressive diseases or asthma, accompanied by respiratory, cardiovascular, and nervous system diseases, and moderate to severe liver or kidney dysfunction; 3. Those who have received any other investigational drug within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| P/F ratio ; | — |
Secondary
| Measure | Time frame |
|---|---|
| OI Index;Physiological Shunt Ratio;respiratory mechanics;Inflammatory markers;Postoperative pulmonary complications; | — |
Countries
China
Contacts
Public ContactChange Zhu
Bozhou People's Hospital
Outcome results
None listed